Evidence map›Paper›PMID 42742463›Full record

ReviewJournal of Parkinson's disease2026

Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape.

Angelo Antonini, Robert E Gross, Maria De Leon, Kevin Kwok, Tom Foltynie, Günter Höglinger, Thomas Gasser, Jean-Christophe Corvol, David J Pedrosa, Jens Volkmann and 1 more

Abstract readReview
In one paragraph

Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Angelo AntoniniNeurodegenerative Diseases Unit, Padova Neuroscience Center, University of Padua, Padua, Italy.ORCID 0000-0003-1040-2807
Robert E GrossRobert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Maria De LeonLived Experience Expert, Nacogdoches, TX, USA.
Kevin KwokLived Experience Expert, Davis Phinney Foundation Board Member, Boulder, CO, USA.ORCID 0009-0007-7691-9143
Tom FoltynieUCL Institute of Neurology, London, UK.
Günter HöglingerLMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.ORCID 0000-0001-7587-6187
Thomas GasserUniversity Hospital of Tübingen, Tübingen, Germany.
Jean-Christophe CorvolSorbonne Université, Paris, France.
David J PedrosaPhilipps-University Marburg, Marburg, Germany.ORCID 0000-0002-5403-1959
Jens VolkmannUniversity of Würzburg, Würzburg, Germany.
Claire HenchcliffeUniversity of California, Irvine, Irvine, California, USA.ORCID 0000-0002-0899-3030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of disease modification should be applicable to both idiopathic and genetic forms of Parkinson's disease. In addition to motor function, it must address important milestones (e.g., cognition, autonomic dysfunction) across all disease stages. This review examines existing definitions and highlights the need for a more holistic approach that integrates the perspectives of patients, healthcare professionals, and researchers.

Indexed as

cell and gene therapiesdisease modificationdisease-modifying therapyparkinson's diseasepatient-reported outcomes

Identifiers

PMID42742463
PMCPMC13578137

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.